Digital PCR is used for a variety of different applications aimed at detecting rare events in complex mixtures and allowing for small fold change differences to be detected. It is indeed like finding a needle in a haystack. 
The QIAGEN digital PCR technology and its expanded capability will not only transform the portfolio of conventional qPCR applications but also provide a more rapid, accurate, and sensitive method for finding answers to difficult biological questions. With its fully integrated and walkaway automation, the nanoplate-based digital PCR will make it easy for you to find the rare positive as a routine.
In this webinar, you’ll learn:
• What is unique to this technology?
• How was it conceived, and how is it being developed?
• What possibilities do you have with the workflow?
About the speaker
Laima Antanaviciute, Ph.D., Market Development Manager – dPCR/PCR
Laima Antanaviciute is the Market Development Manager for digital PCR (dPCR) and PCR at QIAGEN for both United States and Canada regions. She has 10 years of molecular biology and genetics research experience in assay development, validation and quality control including 3 years of experience as a Field Application Scientist (FAS) within the biotechnology industry. Over the past year, she worked as a FAS for the original digital PCR system developed by Formulatrix®, which was later acquired by QIAGEN. Antanaviciute received her M.Phil. and Ph.D. in Biological Sciences from University of Reading in the United Kingdom, during which she published a number of scientific articles reporting her findings in genetic mapping.
Date of recording:Wednesday, April 7, 2021
Duration:1 hour
Academic Basic Research
Molecular Biology
Molecular Biology Research